Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4⁺ tumor infiltrating lymphocytes and their in situ localization.

ABSTRACT: Immune checkpoint inhibitors, including ipilimumab (IPI), achieve a clinical benefit in a small proportion of melanoma patients highlighting the need to investigate predictive biomarkers. In this study, we characterized tumor infiltrating lymphocytes (TILs), focusing on the CTLA-4⁺ subset, and evaluated their possible predictive significance. We characterized TIL density, cell type, and localization in 40 melanoma lesions from 17 patients treated with IPI. Associations of TILs with IPI timing, tissue localization, and response to IPI were estimated using a linear mixed-effects modelling approach. We found that most of TIL subsets increased in situ upon IPI therapy, with particular reference to FoxP3⁺ cells. TILs and TIL subsets, such as CD3⁺, CD45RO^+</

SUBMITTER: Mastracci L 

PROVIDER: S-EPMC11027859 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature